Drug details

Technivie (ombitasvir, paritaprevir and ritonavir tablets)

type of HCV NS5A Inhibitors, HCV Polymerase Inhibitors, HCV Protease Inhibitors

Technivie (ombitasvir, paritaprevir, and ritonavir) is a fixed-dose combination of a hepatitis C virus NS5A inhibitor, a hepatitis C virus NS3/4A protease inhibitor, and a CYP3A inhibitor, and is indicated in combination with ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis.

The drug is often used to treat Cirrhosis , Hepatitis C .

The following drugs are related to Technivie, either as a replacement or used together:

• Avonex (interferon beta-1a)
• Betaseron (interferon beta-1b)
• Victrelis (boceprevir capsules)
• Zepatier (elbasvir and grazoprevir tablets)
• Neupogen (filgrastim injection)
• Releuko (filgrastim-ayow injection)
• Twinrix (hepatitis a inactivated & hepatitis b (recombinant) vaccine)
• Incivek (telaprevir film-coated tablets)
• Intron A - Rebetol (ribavirin, interferon alfa-2b, recombinant)
• Moderiba (ribavirin tablets)
• Olysio (simeprevir hard gelatin capsules)
• Peg-Intron (peginterferon alfa-2b)
• PegIntron and Rebetol Combo Pack (peginterferon alfa-2b and ribavirin combo pack)
• Rebetol (ribavirin)